RxE2

R&D

Pharmacy and clinical research: the pharmaphorum podcast

In the latest episode of the pharmaphorum podcast, pharmaphorum’s web editor Catherine Longworth speaks to Gerald Finken, the founder and CEO of RxE2.

News

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks